← All trials
NCT06944925
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2025
- Primary completion
- Oct 31, 2026
- Completion date
- Mar 31, 2027
- First posted
- Apr 25, 2025
- Last posted
- May 14, 2025
- Enrollment
- 98
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bambusa TherapeuticsLead sponsor
- Bambusa TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.